Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.68 and traded as high as $0.80. Brainstorm Cell Therapeutics shares last traded at $0.7917, with a volume of 4,904 shares changing hands.
Brainstorm Cell Therapeutics Price Performance
The firm has a market cap of $8.50 million, a PE ratio of -0.23 and a beta of 0.30. The firm has a 50-day simple moving average of $0.78 and a 200 day simple moving average of $0.68.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Featured Articles
- Five stocks we like better than Brainstorm Cell Therapeutics
- As AI Data Breaches Become More Common, This Cybersecurity ETF Is SurgingAI
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
